HealthCare Royalty Partners’ Revenue Financing Agreement with Spero Therapeutics

Cadwalader advised HealthCare Royalty Partners on the deal.HealthCare Royalty Partners closed a revenue financing agreement for up to $125 million for Spero Therapeutics, Inc. (NASDAQ: SPRO), a…

This content is for members only.
Login to Read More Join Now
Laura Testa

Author: Laura Testa

This content is for members only.
Login to Read More Join Now